Cord blood boost: new technique shows promise for tough leukemia cases

NCT ID NCT04103879

Completed Disease control Sponsor: ExCellThera inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recover faster with fewer complications. Early results suggest it may improve survival and reduce side effects like graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelogenous leukemia, BCR-ABL1 positive myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORD BLOOD TRANSPLANT HIGH RISK HEMATOLOGICAL MALIGNANCY

Contacts and locations

Locations

Erasmus Medical Center

Rotterdam, Gelderland, 3015, Netherlands
Fred Hutchinson / University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
University of Colorado School of Medicine. Anschutz Medical Campus

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.